Translational Medicine
Open Access
ISSN: 2161-1025
ISSN: 2161-1025
Eleftherios P Diamandis
Department of Laboratory Medicine & Pathobiology
University of Toronto, Canada
Dr. Diamandis currently serves as Division Head of Clinical Biochemistry at Mount Sinai Hospital and Biochemist-in-Chief at the University Health Network and Professor Head, Clinical Biochemisty, University of Toronto, Ontario, Canada. He received his B.Sc. inChemistry, Ph.D. in Analytical Chemistry and M.D. from the University of Athens, Greec and a Diploma in Clinical Biochemistry from the University of Toronto, Canada. He is a Certified Clinical Chemist by the Canadian Academy of Clinical Biochemistry and the American Board of Clinical Chemistry. Dr. Diamandis is a Member of 37 Journal Advisory Scientific and Editorial Boards. He has received numerous awards from both national and international organizations, which include American Association for Clinical Chemistry Award for Outstanding Scientific Achievements by a Young Investigator 1985 Annual Research Excellence Award of the Canadian Society of Clinical Chemists 1995 Distinguished Scientist Award, Clinical Ligand Assay Society CLAS 1999 Distuished Scientist Award, National Academy of Clinical Biochemistry NACB2000 Frey-Werle Commemorative Gold Medal from the Frey Werle Foundation 2007; The International Federation of Clinical Chemistry and Laboratory Medicine IFCC/Abbott Award for Significant Contributions to Molecular Diagnostics 2009 Distinguished Service Award, Department of Laboratory Medicine and Pathobiology, University of Toronto 2010 Excellence in Biomedical Research Nemitsas Prize in Medical Sciences, Takis and Louki Nemitsas Foundation 2010 Named Hold em for Life Chair in Prosate Cancer Biomarkers 2010. Other major distinctions of Dr. Diamandis include his election as Corresponding Member of the Academy of Athens, Greece 2005 Member of the Royal Society of Canada 2008. He has published 95 review papers, 492 research papers and co-authored 4 books and 26 book chapters.
His research activities evolve around discovery and validation of novel cancer biomarkers, proteomics, mass spectrometry and translational research and the role of kallikrein enzymes inhealth and disease basic and translational aspects of tumour metastasis.